Post by Alban Bessede, PhD

We are proud to see the paper out in Cancer Cell by Cell Press from the Memorial Sloan Kettering Cancer Center (MSKCC), led by Jeffrey Ravetch, David Knorr, and colleagues, showing that an Fc-optimized CD40 agonist (2141-V11), delivered intratumorally, can induce tertiary lymphoid structures (#TLS) and drive systemic antitumor immunity—with complete responses reported in melanoma and breast cancer. Beyond the headline result, these findings reinforce a key idea: TLS can be pursued as a therapeutic objective—with the right engineering and delivery, #CD40 agonism can reprogram the tumor microenvironment into a self-sustaining immune ecosystem. https://lnkd.in/dA29wYWa 🔬 Explicyte Immuno-Oncology contribution Explicyte supported this work with multiplex IHF staining, enabling direct visualization of TLS formation in tumor tissue. Warm thanks to Jean-Philippe Guégan and teams for their outstanding collaboration. 📸 Image TLS visualized by multiplex IHF (Explicyte). 🧪 What this showcases about our platform This study highlights how our #translationalresearch platform helps partners measure and interpret the impact of new immunomodulatory agents—from TLS induction and maturation to dendritic-cell activation, HEV density, and chemokine programs—leveraging spatial biology + multiplex IHF with integrated analytics. 🔗 Explore our translational research platform: https://lnkd.in/dAJw-G_X